Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MTLS 
Materialise NV (MTLS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/12/2025: MTLS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8.94
1 Year Target Price $8.94
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -35.75% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 350.27M USD | Price to earnings Ratio 65.89 | 1Y Target Price 8.94 |
Price to earnings Ratio 65.89 | 1Y Target Price 8.94 | ||
Volume (30-day avg) 2 | Beta 1.12 | 52 Weeks Range 3.93 - 9.69 | Updated Date 11/12/2025 |
52 Weeks Range 3.93 - 9.69 | Updated Date 11/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.09 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-28 | When - | Estimate 0.01 | Actual 0.04 |
Profitability
Profit Margin 1.68% | Operating Margin (TTM) 3.81% |
Management Effectiveness
Return on Assets (TTM) 0.71% | Return on Equity (TTM) 1.77% |
Valuation
Trailing PE 65.89 | Forward PE - | Enterprise Value 280341560 | Price to Sales(TTM) 1.33 |
Enterprise Value 280341560 | Price to Sales(TTM) 1.33 | ||
Enterprise Value to Revenue 0.92 | Enterprise Value to EBITDA 8.06 | Shares Outstanding 59067186 | Shares Floating 24298392 |
Shares Outstanding 59067186 | Shares Floating 24298392 | ||
Percent Insiders 5.3 | Percent Institutions 14.2 |
Upturn AI SWOT
Materialise NV
Company Overview
History and Background
Materialise NV was founded in 1990 in Leuven, Belgium. Initially, it focused on rapid prototyping using 3D printing. Over time, it expanded into software, medical, and manufacturing solutions, establishing itself as a leader in additive manufacturing.
Core Business Areas
- Medical: Provides medical image processing, surgical planning, and patient-specific implants and guides using 3D printing technology.
- Software: Develops software platforms for 3D printing and additive manufacturing, offering solutions for design optimization, build preparation, and process control.
- Manufacturing: Offers 3D printing services and solutions for various industries, including aerospace, automotive, and consumer goods.
Leadership and Structure
Materialise is led by CEO Fried Vancraen, who co-founded the company. The organizational structure includes distinct business units for medical, software, and manufacturing, each with dedicated leadership teams.
Top Products and Market Share
Key Offerings
- Mimics Innovation Suite: Software for medical image processing and 3D modeling, used for surgical planning and personalized medical devices. Market share in medical image processing software is estimated to be around 15%. Competitors include Philips, Siemens Healthineers, and GE Healthcare.
- Magics: Data preparation and build optimization software for additive manufacturing. Market share in AM data prep software is around 20%. Competitors include Autodesk Netfabb, and ANSYS.
- OnSite: 3D printing services for industrial and medical applications. Market share data is not readily available. Competitors include Stratasys Direct Manufacturing and 3D Systems On Demand.
Market Dynamics
Industry Overview
The additive manufacturing industry is experiencing rapid growth, driven by increasing demand for customized products, faster prototyping, and advanced manufacturing capabilities. Key trends include the adoption of 3D printing in healthcare, aerospace, and automotive industries.
Positioning
Materialise is positioned as a leading provider of end-to-end 3D printing solutions, with a strong focus on medical and industrial applications. Its competitive advantages include its proprietary software, extensive experience in 3D printing, and established relationships with key industry players.
Total Addressable Market (TAM)
The TAM for additive manufacturing is estimated to reach $55.8 billion by 2027. Materialise is well-positioned to capture a significant share of this market through its diverse product portfolio and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Proprietary software solutions
- Extensive experience in 3D printing
- Established relationships with key industry players
- Diverse product portfolio
Weaknesses
- High R&D costs
- Dependence on 3D printing technology advancements
- Relatively small scale compared to larger competitors
- Profitability can be inconsistent
Opportunities
- Growing demand for customized products
- Increasing adoption of 3D printing in healthcare
- Expansion into new industries and geographies
- Partnerships with medical device and aerospace companies
Threats
- Intense competition from larger companies
- Rapid technological advancements
- Economic downturns affecting capital expenditures
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- DDD
- SSYS
Competitive Landscape
Materialise NV competes with larger companies like 3D Systems and Stratasys. Its strengths lie in its software solutions and medical applications, but it faces challenges in competing on price and scale. Smaller players are taking hold in the different niches as well.
Major Acquisitions
RSPrint
- Year: 2022
- Acquisition Price (USD millions): 1.25
- Strategic Rationale: Acquisition of RSPrint further expands Materialise's portfolio of 3D-printed solutions for foot care, strengthening its position in the growing market for personalized medical devices.
Growth Trajectory and Initiatives
Historical Growth: Materialise NV has experienced steady growth in revenue over the past several years, driven by increasing demand for its 3D printing solutions. The medical segment has been a key growth driver, along with expansion into new industries.
Future Projections: Future growth projections require access to analyst estimates which are not accessible. Please refer to analyst reports.
Recent Initiatives: Recent initiatives include expanding its software platform, investing in new 3D printing technologies, and forming partnerships with medical device companies.
Summary
Materialise NV is a prominent player in the additive manufacturing industry, particularly in the medical and software sectors. Its strengths include innovative software and a strong foothold in personalized medicine. However, it faces stiff competition from larger companies and needs to manage its high R&D costs effectively to maintain profitability. Recent strategic initiatives and acquisitions show a focus on continued growth and market expansion.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Filings
- Industry Reports
- Analyst Reports (where available - public domain)
- Company Website
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is based on estimates and may vary. Financial data is not real-time and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Materialise NV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2014-06-25 | CEO - | ||
Sector Technology | Industry Software - Application | Full time employees 488 | Website https://www.materialise.com |
Full time employees 488 | Website https://www.materialise.com | ||
Materialise NV provides additive manufacturing and medical software tools, and 3D printing services in the Americas, Europe, Africa, and the Asia-Pacific. The company operates through three segments: Materialise Software, Materialise Medical, and Materialise Manufacturing. The Materialise Software segment offers software through programs and platforms that enable and enhance the functionality of 3D printers, and printing operations. Its software interfaces between various types of 3D printers; and various software applications and capturing technologies, including computer-aided design/computer-aided manufacturing packages and 3D scanners; a MES, software providers. This segment serves 3D printing machine manufacturers; production companies and contract manufacturers in automotive, aerospace, consumer goods, and hearing aid industries; and 3D printing service bureaus through its sales force, website, and third-party distributors. The Materialise Medical segment provides medical software that allows medical-image based analysis, planning, and engineering, as well as patient-specific design and printing of surgical devices and implants. It serves medical device companies, hospitals, universities, research institutes, and industrial companies through its direct sales force, website, and picture archiving and communication system. The Materialise Manufacturing segment provides 3D printing services, design and engineering services, and rapid prototyping and additive manufacturing of production parts to customers serving the automotive, consumer goods industrial goods, semiconductor, art and architecture and aerospace markets. The company has collaboration agreements with Zimmer Biomet Holdings, Inc.; Encore Medical, L.P.; DePuy Synthes Companies of Johnson & Johnson; Limacorporate Spa; Mathys AG; Smith & Nephew Inc.; Corin Ltd; Medtronic Inc.; and Abbott Laboratories Inc. Materialise NV was incorporated in 1990 and is headquartered in Leuven, Belgium.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.